Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858.

ABSTRACT: We recently reported that the accumulation of myeloid-derived suppressor cells (MDSC), defined as CD33⁺HLA-DR^-Lin^-, has a direct role in the pathogenesis of myelodysplastic syndrome (MDS). In particular, CD33 is strongly expressed in MDSC isolated from patients with MDS where it has an important role in MDSC-mediated hematopoietic suppressive function through its activation by S100A9. Therefore, we tested whether blocking this interaction with a fully human, Fc-engineered monoclonal antibody against CD33 (BI 836858) suppresses CD33-mediated signal transduction and improves the bone marrow microenvironment in MDS. We observed that BI 836858 can reduce MDSC by antibody-dependent cellular cytotoxicity, which correlated with increases in granule mobilization an

SUBMITTER: Eksioglu EA 

PROVIDER: S-EPMC5552472 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature